Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 1/2 2Phase 3 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Gastrointestinal 3Thoracic 2Genitourinary 2Breast 2Dermatologic 1

Conditions

Melanoma 56Carcinoma, Non-Small-Cell Lung 56Carcinoma, Renal Cell 34Neoplasms 33Neoplasm Metastasis 29Colorectal Neoplasms 23Squamous Cell Carcinoma of Head and Neck 22Pancreatic Neoplasms 22Carcinoma, Hepatocellular 21Carcinoma, Transitional Cell 18Lung Neoplasms 17Glioblastoma 15Ovarian Neoplasms 14Triple Negative Breast Neoplasms 13Breast Neoplasms 13Urinary Bladder Neoplasms 11Stomach Neoplasms 11Head and Neck Neoplasms 10Uveal Melanoma 9Recurrence 8Myelodysplastic Syndromes 8Lymphoma 8Leukemia, Myeloid, Acute 8Advanced Cancer 8Small Cell Lung Carcinoma 7Multiple Myeloma 7Kidney Neoplasms 7Hodgkin Disease 7Hematologic Neoplasms 7Glioma 7

Interventions

Paclitaxel 29Carboplatin 25Topotecan 12Gemcitabine 11Cyclophosphamide 11Cisplatin 11Taxes 10Filgrastim 9sargramostim 8pembrolizumab 8Docetaxel 8Bevacizumab 8Peripheral Blood Stem Cell Transplantation 6liposomal doxorubicin 5Flow Cytometry 5Interleukin-12 Subunit p35 4Drug Therapy 4fludarabine phosphate 3fludarabine 3Sirolimus 3Nivolumab 3Melphalan 3Immunohistochemistry 3Immunoenzyme Techniques 3Granulocyte-Macrophage Colony-Stimulating Factor 3Fulvestrant 3Etoposide 3Chemotherapy, Adjuvant 3Capecitabine 31-dodecylpyridoxal 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Ovarian Epithelial × Nivolumab × Clear all
NCT07334119 2026-05-20

Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

Myeloid Therapeutics

Phase 1 Recruiting
60 enrolled
BreastGastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma Of Esophagus, Carcinoma, Ovarian Epithelial, Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Toray Industries, Inc

Phase 1 Active not recruiting
138 enrolled
DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT04925284 2025-04-04

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

Exelixis

Phase 1 Completed
269 enrolled
BreastGastrointestinalGynecologicThoracic

Carcinoma, Ovarian Epithelial, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Pancreatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡